OCT can characterize corneoscleral junction

Article

Optical coherence tomography (OCT) can be used to characterize the angle and topography of the corneoscleral junction, according to newly published research.

Optical coherence tomography (OCT) can be used to characterize the angle and topography of the corneoscleral junction, according to research published in Optometry and Vision Science.

The novel, quantitative method used by the researchers also established differences among quadrants of the ocular surface, and between ethnic groups.

The researchers recruited a total of 48 subjects (16 Asian, 16 White and 16 Latino), and took OCT images in both eyes of the subjects' nasal, temporal, superior and inferior quadrants. Custom image analysis software allowed selection of a point defining the centre of the corneoscleral junction, and 20 concentric circles were drawn from this point. Edge-detection routines located the surface of the junction, and a linear regression was fit to the series of points that defined the circles intersecting this edge. A set of metrics was then calculated based on the regression residuals.

The researchers found that the most repeatable metric was the sum of the squared orthogonalized residuals (SSRo). In addition, this metric was unaffected by the orientation of the image.

The SSRo was greatest (indicating a more pronounced angle and/or rougher surface) in the nasal quadrant (p p

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.